Easy to brush over RAC's preclinical results by dismissing them as "just preclinical" when you don't understand the context and history of Zantrene and about RAC's strategy in pivoting/repurposing it. Doesn't help when it is a first in class drug with no baseline level of understanding/awareness. It actually takes time to understand the RAC opportunity and the market is full of people with goldfish attention spans looking for the next sugar rush.
RAC - Charts & Price Action, page-11886
-
- There are more pages in this discussion • 11,160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.42 |
Change
0.000(0.00%) |
Mkt cap ! $246.3M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $108.3K | 76.53K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14331 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 11181 | 2 |
View Market Depth
| Last trade - 14.07pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |